Investment Manager, IPO and Mergers and Acquisitions

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Investment Manager

IPO

Mergers and Acquisitions

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

JANUARY 23, 2024

For example, in the biopharma space, AbbVie, Bristol Myers Squibb, AstraZeneca, and Roche each announced multiple big-ticket acquisitions in the fourth quarter – including Abbvie’s acquisition of ImmunoGen for $10.1 billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion and Cerevel Therapeutics for $8.7

M&A

M&A Mergers and Acquisitions Pharmaceutical Acquisitions

Cooley’s 2021 Tech M&A Year in Review

Cooley M&A

JANUARY 20, 2022

While R&W insurance has been a staple for private equity buyers for several years, the increased adoption of R&W insurance by strategic acquirers in acquisitions of private targets is a notable trend – almost 30% of all R&W policies in 2021 were procured by strategic buyers. [1].

M&A

M&A Insurance Mergers and Acquisitions IPO

Investment Banking Today

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley’s 2021 Tech M&A Year in Review

Stay Connected